

References

1. Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, et al. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307. *Epilepsia*. 2018;59:866–76.
2. French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. *Neurology*. 2015;85:950–7.
3. Gayatri NA, Livingston JH. Aggravation of epilepsy by anti-epileptic drugs. *Dev Med Child Neurol*. 2006;48:394–8.
4. Villanueva V, Montoya J, Castillo A, Mauri-Llerdà JÁ, Giner P, López-González FJ, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study. *Epilepsia*. 2018;59:1740–52.
5. Biro A, Stephani U, Tarallo T, Bast T, Schlachter K, Flegler M, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. *Neuropediatrics*. 2015;46:110–6.
6. Swiderska N, Tan HJ, Rajai A, Silwal A, Desurkar A, Martland T. Effectiveness and tolerability of perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study. *Seizure*. 2017;52:63–70.

Anna Duat Rodríguez^{a,*}, Verónica Cantarín Extremera^a, Marta García Fernández^b, Juan José García Peñas^a, María Luz Ruiz-Falcó Rojas^a

^a Servicio de Neurología, Hospital Universitario Niño Jesús, Madrid, Spain

^b Servicio de Neurofisiología, Hospital Universitario Niño Jesús, Madrid, Spain

* Corresponding author.

E-mail address: anna.duat@salud.madrid.org

(A. Duat Rodríguez).

2341-2879/

© 2019 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

An update of the recommendations of the spanish neonatology society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants[☆]



Recomendaciones de la sociedad española de neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización

To the Editor:

Bronchiolitis, and in particular bronchiolitis caused by respiratory syncytial virus (RSV), is the leading cause of hospital admission in infants aged less than 1 year in Spain. Healthy infants born to term are the infants that require admission due to RSV bronchiolitis most frequently, however, infants in the at-risk group, that is, those born preterm, with bronchopulmonary dysplasia (BPD), with haemodynamically significant congenital heart defects, Down syndrome, neuromuscular disorders or velocardiofacial syndrome are at higher risk of developing severe disease.¹

General preventive measures such as breastfeeding, hand hygiene and avoiding exposure to tobacco smoke or crowding

are essential. However, in the group of patients at highest risk of severe RSV infection, palivizumab continues to be the only drug authorised for pharmacological prophylaxis.

In 2014, the American Academy of Pediatrics (AAP) published new guidelines with particular emphasis on economic aspects calling for a significant restriction in the use of palivizumab prophylaxis, which have remained without changes in a recent publication.²

Recently, the Standards Committee of the Sociedad Española de Neonatología (Spanish Society of Neonatology, SENe) concluded that the new guideline of the AAP did not contribute additional scientific evidence calling for any changes in the current recommendations for Spain. However, and with the aim of reducing the economic impact of palivizumab prophylaxis due to its high cost, the Committee proposed modifications to ensure its correct and rational use.³

There has been evidence of an increase in the incidence of severe disease due to RSV infection in inpatient populations, especially in infants born preterm, who in the past used to receive prophylaxis but stopped receiving it following the changes in the recommendations of the AAP in 2014, accompanied by a considerable increase in the costs associated with hospitalization.⁴

In this sense, the most drastic cut recommended by the AAP concerned the population of infants born preterm at or after 29 weeks' gestation. There is no question that this is a fairly large population, but it is one in which the proportion of RSV infections that produce severe disease requiring hospital admission is very high. For this reason, the Standards Committee of the SENe³ determined that there is a higher-risk group within this population that, if identified accurately, comprises patients that could benefit greatly from prophylaxis in both the short and the long term, as corroborated by recent evidence.⁵

The AAP, based on data from descriptive study,⁶ determined that the use of risk factors as predictors in the

[☆] Please cite this article as: Sánchez Luna M, et al. Recomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización. *An Pediatr (Barc)*. 2019;91:348–350.

population aged less than 5 years does not allow a clear definition of the subsets that would most benefit from prophylaxis, and therefore concluded that it is not justified for the purpose of identifying at-risk populations.

However, the use of risk factors based on data from well-designed studies in populations at high risk of hospitalization due to bronchiolitis has demonstrated that this approach can correctly identify the groups that could most benefit from prophylaxis, especially in the case of studies that include data from the population of the country of interest.⁷

Recent evidence has demonstrated that in this high-risk group, the use of palivizumab prophylaxis is cost-effective taking into consideration nationwide data and using a societal perspective for the first time.⁸

Patients with BPD constitute a group at high risk of developing RSV-associated severe illness requiring hospitalization, even after 12 months of age. It has been established that at ages 18–24 months, the risk of requiring hospitalization due to severe RSV infection in these patients is as high as the risk in infants born to term in the first 2 months of life (10%–12%).⁹ This clearly demonstrates the importance of maintaining prophylaxis in this population.

A consensus document has been recently published proposing recommendations based on a systematic review of the literature and the best clinical evidence published between 2013 and 2018.¹⁰

This document defines age groups and high-risk groups that may benefit more from prophylaxis, such as infants born preterm between 29 and 31 weeks' gestation and infants born preterm after 32 weeks' gestation based on their risk factors, and maintains the recommendation of prophylaxis in children with Down syndrome, immunosuppression, haemodynamically significant congenital heart defects, neuromuscular disorders or cystic fibrosis.¹⁰

Based on the best current scientific evidence,¹⁰ the Standards Committee of the SENEo maintains the recommendations issued in 2015,³ reinforcing the role of risk factors in the identification of subsets of infants born preterm between 32 and 35 weeks' gestation and the application of individualised clinical criteria in patients with BPD during the second year of life (Table 1).

Conflicts of interest

MSL has participated in conferences and working groups funded in part by AbbVie and Sanofi. SRG has participated in conferences and working groups funded by AbbVie.

References

1. Sanchez-Luna M, Elola FJ, Fernandez-Perez C, Bernal JL, Lopez-Pineda A. Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004-2012. *Curr Med Res Opin.* 2016;32(4):693–8.
2. Munoz FM, Ralston SL, Meissner HC. RSV recommendations unchanged after review of new data. *AAP News.* 2017;38:1–4.
3. Figueras Aloy J, Carbonell Estrany X. Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial. *An Pediatr (Barc).* 2015;82(3):199, e1-2.

Table 1 Recommendations for prophylaxis.

Recommendations for prophylaxis with palivizumab in preterm infants without BPD or congenital heart defects (3, 10):

[●] Gestational age $\leq 28^{+6}$ months and age ≤ 9 months at beginning of RSV season

- Gestational age 29^{+0} to 31^{+6} months and age ≤ 6 months at beginning of RSV season.
- Gestational age 32^{+0} to 34^{+6} months meeting the 2 major criteria: age less than 10 weeks at beginning of RSV season (born from August 6th, included) and with at least one sibling attending school or a childcare centre.

Recommendations for prophylaxis with palivizumab in patients with BPD (3, 10):

[●] All in the first year of chronological age.

- In the second year, prophylaxis is recommended in those with persistent need of medical treatment or in whom it is considered appropriate due to the high risk of the patient based on clinical condition.

Dose: 15 mg/kg monthly throughout the RSV season (maximum of 5 doses).

4. Kong AM, Krilov LR, Fergie J, Goldstein M, Diakun D, Wade SW, et al. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States. *Am J Perinatol.* 2018;35:192–200.
5. Straňák Z, Saliba E, Kosma P, Posfay-Barbe K, Yunis K, Farstad T, et al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI). *PLoS One.* 2016;11:e0157446.
6. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med.* 2009;360(6):588–98.
7. Blanken MO, Paes B, Anderson EJ, Lanari M, Sheridan-Pereira M, Buchan S, et al. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. *Pediatr Pulmonol.* 2018;53(5):605–12.
8. Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martín-Torres F, et al. Cost-utility analysis of palivizumab for respiratory syncytial virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. *BMC Infect Dis.* 2017;17(1):687.
9. Winterstein AG, Choi Y, Meissner HC. Association of age with risk of hospitalization for respiratory syncytial virus in preterm infants with chronic lung disease. *JAMA Pediatr.* 2018;172(2):154–60.
10. Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, et al. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. *Paediatr Respir Rev.* 2018. <http://dx.doi.org/10.1016/j.prrv.2018.12.001>.

Manuel Sánchez Luna

Hospital General Universitario Gregorio Marañón, Madrid, Spain

Alejandro Pérez Muñuzuri

Hospital Clínico Universitario, Santiago de Compostela, Spain

José Luis Leante Castellanos

Hospital General Universitario Santa Lucía, Cartagena, Spain

César W. Ruiz Campillo

Hospital Universitario Vall d'Hebron, Barcelona, Spain

Ester Sanz López

Hospital General Universitario Gregorio Marañón, Madrid, Spain

Isabel Benavente Fernández

Hospital Universitario Puerta del Mar, Cádiz, Spain

María Dolores Sánchez Redondo

Hospital Virgen de la Salud, Complejo Hospitalario de Toledo, Toledo, Spain

Segundo Rite Gracia*, en representación de la Comisión de Estándares de la Sociedad Española de Neonatología

‡ *Hospital Universitario Miguel Servet, Zaragoza, Spain*

* Corresponding autor.

E-mail address: sriteg@salud.aragon.es (S.R. Gracia).

22 July 2019 8 August 2019

2341-2879/

© 2019 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).